Vicus Therapeutics | Date: 2006-01-19
Vicus Therapeutics | Date: 2012-03-08
In alternative embodiments the invention provides compositions, e.g., pharmaceutical compositions and preparations, formulations, kits and other products of manufacture, e.g., exemplary drug combinations packaged together or separately in blister packs, lidded blisters or blister cards, or wrapped in paper, plastic or cellophane wrappers (e.g., a shrink wrap), comprising a combination regimen of at least two active ingredients designed to diminish systemic inflammation by targeting (inhibiting) two different, but convergent, signaling pathways, i.e., the sympathetic nervous system and the lipid-derived autacoid system; and methods for making and using these compositions. In alternative embodiments, the compositions of the invention (e.g., the combination of drugs) are used to ameliorate, diminish, treat, block or prevent an inflammatory response secondary to an infection, e.g., a viral infection and/or a reactivation.
Turner T.J.,Vicus Therapeutics |
Bascomb N.,Vicus Therapeutics |
Maki J.,Vicus Therapeutics |
Rao N.,Vicus Therapeutics |
Young F.S.,Vicus Therapeutics
Drug Discovery Today: Therapeutic Strategies | Year: 2012
We define 'orphaned drugs' as those proven drugs that have been abandoned because of a perceived inability to develop them commercially for new indications. Using a hierarchical-network ('HiNET') algorithm applied to a disease of interest,we identify the probable drug candidates for repurposing based on the similarity principle. Here, we describe an approach for selection and commercial development of multidrug regimens using innovative analytical and business models. © 2011 Elsevier Ltd. All rights reserved.